Ionis Pharmaceuticals IONS Contract Assets
Contract Assets at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNetCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's contract assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's contract assets?
- Ionis Pharmaceuticals (IONS) reported contract assets of $73.68M in Q1 2026.
- How has Ionis Pharmaceuticals's contract assets changed year-over-year?
- Ionis Pharmaceuticals's contract assets increased by 85.6% year-over-year, from $39.71M to $73.68M.
- What is the long-term trend for Ionis Pharmaceuticals's contract assets?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's contract assets has grown at a -2.8% compound annual growth rate (CAGR), from $76.2M to $66.06M.
- What does contract assets mean?
- The value of work performed or goods delivered for which the company has not yet issued an invoice.
- How do you interpret contract assets?
- An increase may indicate strong progress on research milestones or service delivery, while a decrease suggests the conversion of these assets into billed accounts receivable.
- How does contract assets compare across companies?
- Common in biotech firms with collaborative research agreements and milestone-based revenue models.